The use of the two different promoters led to different tumor types: the gfap promoter drove expression in CNS with 50% incidence of tumor development; the krt5 promoter induced aggressive nerve sheath tumors, supporting the idea that the origin of the tumor initiating cells affect tumor cell types [114]. This evidence concerns the gene GFAP and neoplasm.